Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
JHEP Reports : Innovation in Hepatology|January 3, 2022
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitisYi Luo, Benjamin E Decato, Edgar D Charles, et al.
Blood|March 23, 2011
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subsetEdgar D Charles, Claudia Brunetti, Svetlana Marukian, et al.
Blood|October 19, 2007
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemiaEdgar D Charles, Rashidah M Green, Svetlana Marukian, et al.
Hepatology Communications|May 24, 2021
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASHYi Luo, Samir Wadhawan, Alex Greenfield, et al.
Clinical and Translational Gastroenterology|April 3, 2019
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT StudyIra M Jacobson, Fred Poordad, Roberto Firpi-Morell, et al.
JHEP Reports : Innovation in Hepatology|March 3, 2023
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trialElizabeth A Brown, Anne Minnich, Arun J Sanyal, et al.
Hepatology (Baltimore, Md.)|October 4, 2021
BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trialEric J Lawitz, Diane E Shevell, Giridhar S Tirucherai, et al.
Lancet (London, England)|December 18, 2018
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trialArun Sanyal, Edgar D Charles, Brent A Neuschwander-Tetri, et al.
Blood|April 30, 2005
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis CDavid Butera, Svetlana Marukian, Amy E Iwamaye, et al.
International Journal of Molecular Sciences|June 24, 2022
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and FibrosisTobias Puengel, Sander Lefere, Jana Hundertmark, et al.
Pageof 3